Mercado Libre Announces Closing of Inaugural Debt Offering – Padovanews padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
SANOFI unveils EUROAPI as the name of the new industry leading European API company and .
SanofiJanuary 12, 2021 GMT
SANOFI unveils EUROAPI as the name of the new industry leading European API company and appoints Karl Rotthier as its future Chief Executive Officer
The new company1 will be the largest API player in the European Union, with approximately €1 billion in expected sales by 2022
Karl Rotthier joins Sanofi as EUROAPI Chief Executive Officer and further lead the creation of this new Europe-based industry champion
EUROAPI will help securing significant API manufacturing and supply capacities that are critical for patients in Europe and beyond
Sanofi: SANOFI unveils EUROAPI as the name of the new industry leading European API company and appoints Karl Rotthier as its future Chief Executive Officer
The new company
1 will be the largest API player in the European Union, with approximately €1 billion in expected sales by 2022
Karl Rotthier joins Sanofi as EUROAPI Chief Executive Officer and further lead the creation of this new Europe-based industry champion
EUROAPI will help securing significant API manufacturing and supply capacities that are critical for patients in Europe and beyond
An IPO on Euronext Paris will be evaluated for 2022 - subject to market conditions
Paris - January 12
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment
Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection
Trial targeted to begin in 1Q:2021 at multiple sites across the UK
SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enh